ReviewAntibiotics (Basel, Switzerland)2021
Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study.Antibiotics (Basel, Switzerland) · 2025Article
- Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study.Infectious diseases and therapy · 2025Article
- Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producingFrontiers in microbiology · 2024Article
- Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-ResistantOpen forum infectious diseases · 2023Article
- Resistance to Ceftazidime/Avibactam inAntibiotics (Basel, Switzerland) · 2023Article
- Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study.Antibiotics (Basel, Switzerland) · 2023Article
- Review
- Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producingJAC-antimicrobial resistance · 2022Article
- Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.Antibiotics (Basel, Switzerland) · 2022Article
- High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The worldwide propagation of antimicrobial resistance represents one of the biggest threats to global health and development. Multi-drug-resistant organisms (MDROs), including carbapenem-resistant non-fermenting Gram-negatives and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.